|
BP13718
|
BI-9564
|
|
|
|
|
BI-9564, a specific cell-permeable BRD9 BD inhibitor. The Kd for BRD9 is 5.9 nM, and IC50 for BET family is > 100 μM.
|
|
BP13717
|
BI-7273
|
|
|
|
|
BI-7273 is an effective, specific, BRD9 BD Inhibitor, which can infiltrate cell.
|
|
BP13716
|
BGP-15
|
|
|
|
|
BGP-15 is a PARP inhibitor with protecting effect after ischemia-reperfusion injury.
|
|
BP13715
|
Pamiparib
|
|
|
|
|
BGB-290 is an orally active, potent, highly selective PARP inhibitor(IC50 of 0.9 nM and 0.5 nM for PARP1 and PARP2, respectively). It has potent PARP trapping, and capability to penetrate the brain, and can be used for the research of various cancers including the solid tumor
|
|
BP13714
|
BET-IN-6
|
|
|
|
|
BET-IN-6 is an effective and high-affinity inhibitor of BRD2/BRD4. It is the ligand for target protein BRD2/4 and is used for the synthesis of PROTAC BRD2/BRD4 degrader-1.
|
|
BP13713
|
ODM-207
|
|
|
|
|
BET-IN-4 is a potent BRD4 inhibitor.
|
|
BP13712
|
BET-IN-2
|
|
|
|
|
BET-IN-2 is a BET inhibitor (IC50: 52 nM for BRD4-BD1).
|
|
BP13711
|
BETd-260
|
|
|
|
|
BETd-260 is a potent degrader of BET based on PROTAC technology, with as low as 30 pM against BRD4 protein in RS4;11 leukemia cell line.
|
|
BP13710
|
BET bromodomain inhibitor
|
|
|
|
|
BET bromodomain inhibitor is a potent BET inhibitor.
|
|
BP13709
|
4-Phenylbutyric acid
|
|
|
|
|
Benzenebutyric acid is an inhibitor of HDAC,and is an antineoplastic agent.
|
|
BP13708
|
Benzamide
|
|
|
|
|
Benzamide, an inhibitor of poly(ADP-ribose) polymerase, is a derivative of benzoic acid.
|
|
BP13707
|
Belinostat
|
|
|
|
|
Belinostat is a novel hydroxamic acid-type histone deacetylase (HDAC) inhibitor with antineoplastic activity. Belinostat targets HDAC enzymes, thereby inhibiting tumor cell proliferation, inducing apoptosis, promoting cellular differentiation, and inhibiting angiogenesis. This agent may sensitize drug-resistant tumor cells to other antineoplastic agents, possibly through a mechanism involving the down-regulation of thymidylate synthase.
|
|
BP13706
|
BEBT-908
|
|
|
|
|
BEBT-908 is a selective PI3Kα inhibitor (IC50 <0.1 μM). BEBT-908 also inhibits HDAC (0.1 μM≤IC50≤1 μM).
|
|
BP13705
|
BCI-121
|
|
|
|
|
BCI-121 is a substrate-competitive SMYD3 inhibitor that inhibits the proliferation of the cancer cell.
|
|
BP13704
|
BAZ2-ICR
|
|
|
|
|
BAZ2-ICR is an epigenetic chemical probe and it also is a potent, selective, cell active and orally active BAZ2A/B bromodomains inhibitor with IC50s of 130 nM and 180 nM, and Kds of 109 nM and 170 nM, respectively. BAZ2-ICR shows 10-15-fold selectivity for binding BAZ2A/B over CECR2 and >100-fold selectivity over all other bromodomains.
|
|
BP13703
|
BAZ1A-IN-1
|
|
|
|
|
BAZ1A-IN-1 is a potent BAZ1A inhibitor with the KD value of 0.52 μM for the BAZ1A bromodomain. BAZ1A-IN-1 shows good anti-survival activity against cancer cell lines with high BAZ1A expression, but weak or no activity against cancer cells with low BAZ1A expression.
|
|
BP13702
|
BAY-6035
|
|
|
|
|
BAY-6035 is an inhibitor of SET and MYND domain-containing protein 3 (SMYD3). BAY-6035 has more than 100-fold selectivity over other histone methyltransferases.
|
|
BP13701
|
BAY-598
|
|
|
|
|
BAY-598 is a selective inhibitor of SMYD2 with IC50 values of 27 nM.
|
|
BP13700
|
BAY1238097
|
|
|
|
|
BAY1238097 is a potent and selective inhibitor of BET binding to histones and has strong anti-proliferative activity in different MM (multiple myeloma) and AML (acute myeloid leukemia) models through down-regulation of c-Myc levels and its downstream transcriptome (IC50 <100 nM).
|
|
BP13699
|
AZD-9574
|
|
|
|
|
AZD-9574 is a selective inhibitor of PARP1 at the sites of SSBs. AZD-9574 exhibits anti-cancer activities and can be used in studies about HRD+ breast cancer and advanced solid malignancies.
|
